Literature DB >> 21446109

[Alexithymia and suicide risk among patients with schizophrenia: preliminary findings of a cross-sectional study].

Viviana Marasco1, Domenico De Berardis, Nicola Serroni, Daniela Campanella, Tiziano Acciavatti, Mario Caltabiano, Luigi Olivieri, Gabriella Rapini, Alessandra Cicconetti, Alessandro Carano, Raffaella La Rovere, Giuseppe Di Iorio, Francesco Saverio Moschetta, Massimo Di Giannantonio.   

Abstract

OBJECTIVE: The aim of the present study was to evaluate the prevalence of alexithymia and its relationships with psychopathological features and suicide risk in a sample of adult patients with a DSM-IV diagnosis of paranoid schizophrenia.
METHODS: A mixed male-female sample of 60 subjects (30 males and 30 females) was evaluated with the following rating scales: Toronto Alexithymia Scale (TAS-20), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Calgary Depression Scale for Schizophrenia (CDSS), Scale for Suicidal Ideation (SSI), State-Trait Anxiety Inventory (STAI).
RESULTS: 22 subjects (36.7%) were categorized as alexithymic (TAS-20 scores > or =61). Alexithymics showed more severe negative and depressive symptoms and increased suicide risk than non alexithymics. However, the results of a linear regression with SSI score as dependent variable showed that Difficulty in Identifying and Describing Feelings dimensions of TAS-20 and higher CDSS scores were significantly associated with higher scores on the Scale for Suicide Ideation.
CONCLUSIONS: The presence of alexithymia in schizophrenia may be related to higher risk of suicide ideation and more severe depressive symptoms, independently by the severity of positive and negative symptoms. However, results are preliminary and limitations must be considered.

Entities:  

Mesh:

Year:  2011        PMID: 21446109

Source DB:  PubMed          Journal:  Riv Psichiatr        ISSN: 0035-6484            Impact factor:   1.911


  4 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup.

Authors:  Domenico De Berardis; Nicola Serroni; Stefano Marini; Gabriella Rapini; Alessandro Valchera; Michele Fornaro; Monica Mazza; Felice Iasevoli; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Case Rep Psychiatry       Date:  2013-05-16

Review 3.  Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review.

Authors:  Domenico De Berardis; Michele Fornaro; Laura Orsolini; Alessandro Valchera; Alessandro Carano; Federica Vellante; Giampaolo Perna; Gianluca Serafini; Xenia Gonda; Maurizio Pompili; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

4.  Editorial: Understanding the Complex Phenomenon of Suicide: From Research to Clinical Practice.

Authors:  Domenico De Berardis; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Front Psychiatry       Date:  2018-03-01       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.